Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.

ADAPT Research Group, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M.

Neurology. 2007 May 22;68(21):1800-8. Epub 2007 Apr 25.

PMID:
17460158
2.

Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.

Daniels S, Robbins J, West CR, Nemeth MA.

Clin Ther. 2009 Jun;31(6):1192-208. doi: 10.1016/j.clinthera.2009.06.003.

PMID:
19695387
3.

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.

Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G; SUCCESS-I Investigators.

Am J Med. 2006 Mar;119(3):255-66. Erratum in: Am J Med. 2006 Sep;119(9):801.

PMID:
16490472
4.

Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.

Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, Chan AO, Wong J, Lam SK.

Am J Med. 2005 Nov;118(11):1271-8.

PMID:
16271912
5.

Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.

Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS.

J Rheumatol. 2000 Aug;27(8):1876-83.

PMID:
10955327
6.

Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.

Goldstein JL, Cryer B, Amer F, Hunt B.

Clin Gastroenterol Hepatol. 2007 Oct;5(10):1167-74.

PMID:
17916545
7.

A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis.

Foeldvari I, Szer IS, Zemel LS, Lovell DJ, Giannini EH, Robbins JL, West CR, Steidle G, Krishnaswami S, Bloom BJ.

J Rheumatol. 2009 Jan;36(1):174-82. doi: 10.3899/jrheum.080073.

PMID:
19012356
10.

Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results.

ADAPT Research Group, Meinert CL, McCaffrey LD, Breitner JC.

Alzheimers Dement. 2009 Mar;5(2):93-104. doi: 10.1016/j.jalz.2008.09.004.

11.

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.

Arch Intern Med. 2005 Jan 24;165(2):161-8. Erratum in: Arch Intern Med. 2005 Mar 14;165(5):551.

PMID:
15668361
12.
13.

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.

Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS.

Am J Gastroenterol. 2001 Apr;96(4):1019-27.

PMID:
11316141
14.

Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.

Becker MC, Wang TH, Wisniewski L, Wolski K, Libby P, L├╝scher TF, Borer JS, Mascette AM, Husni ME, Solomon DH, Graham DY, Yeomans ND, Krum H, Ruschitzka F, Lincoff AM, Nissen SE; PRECISION Investigators.

Am Heart J. 2009 Apr;157(4):606-12. doi: 10.1016/j.ahj.2008.12.014. Epub 2009 Feb 25.

PMID:
19332185
15.

Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis.

Barkhuizen A, Steinfeld S, Robbins J, West C, Coombs J, Zwillich S.

J Rheumatol. 2006 Sep;33(9):1805-12.

PMID:
16960941
16.

Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.

White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, Weiner E, Verburg KM.

Am J Cardiol. 2007 Jan 1;99(1):91-8. Epub 2006 Nov 10.

PMID:
17196469
17.

Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.

Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM, Geis GS.

Am J Gastroenterol. 2000 Jul;95(7):1681-90.

PMID:
10925968
19.

A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury.

Scheiman JM, Cryer B, Kimmey MB, Rothstein RI, Riff DS, Wolfe MM.

Clin Gastroenterol Hepatol. 2004 Apr;2(4):290-5.

PMID:
15067622
20.

Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.

Goldstein JL, Zhao SZ, Burke TA, Palmer R, von Allmen H, Henderson SC.

Am J Gastroenterol. 2003 Dec;98(12):2627-34.

PMID:
14687808

Supplemental Content

Support Center